Eli Lilly and Co. LLY on Thursday released promising long-term data regarding its treatment for Crohn’s disease. This news ...

Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price?

A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment was for the co-innovation lab. This article has been updated to reflect the change. If there ...

Eli Lilly isn't a one-trick pony.

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly has quietly turned a blockbuster obesity and diabetes franchise into one of the market's most intriguing income stories. The company's rapid growth, aggressive capital returns, and ...